<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40897264</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1665-2681</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Annals of hepatology</Title><ISOAbbreviation>Ann Hepatol</ISOAbbreviation></Journal><ArticleTitle>A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined comprehensive treatment for hepatocellular carcinoma.</ArticleTitle><Pagination><StartPage>102106</StartPage><MedlinePgn>102106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aohep.2025.102106</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1665-2681(25)00331-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with intra-arterial bevacizumab infusion in patients with advanced hepatocellular carcinoma (HCC).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In this prospective randomized controlled trial, 120 patients with advanced HCC (stages Ib-IIIb) were enrolled between March 2021 and October 2023 and randomized to receive TACE alone (control group, n&#x202f;=&#x202f;60) or TACE plus intra-arterial bevacizumab (combined group, n&#x202f;=&#x202f;60). Tumor perfusion parameters were assessed via dynamic contrast-enhanced MRI (DCE-MRI), while VEGF and SDF-1 levels were measured using ELISA. Efficacy, safety, and adverse events were compared between groups. Efficacy analyses for tumor response were based on 58 patients per group with complete imaging data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The combined group exhibited significant reductions in DCE-MRI parameters, including transfer coefficient, blood flow, and plasma volume (all P&#x202f;&lt;&#x202f;0.05). Complete response (CR) rates were 0&#x202f;% in both groups (P&#x202f;&gt;&#x202f;0.05). Partial response (PR) rates were higher in the combined group (27.6&#x202f;% vs. 6.9&#x202f;%, P&#x202f;&lt;&#x202f;0.05), as were stable disease (SD) rates (60.3&#x202f;% vs. 34.5&#x202f;%, P&#x202f;&lt;&#x202f;0.05). Total disease control (CR+PR+SD) was significantly improved in the combined group (87.9&#x202f;% vs. 41.4&#x202f;%, P&#x202f;&lt;&#x202f;0.05). Liver/kidney function and adverse event rates (e.g., hypertension, 8.3&#x202f;% in combined group) were comparable between groups (P&#x202f;&gt;&#x202f;0.05), though proteinuria was more frequent in the combined group (6.7&#x202f;% vs. 0&#x202f;%, P&#x202f;=&#x202f;0.043).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intra-arterial bevacizumab combined with TACE enhances tumor response and disease control in advanced HCC without a substantial increase in overall toxicity, providing a promising locoregional anti-angiogenic strategy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Fundaci&#xf3;n Cl&#xed;nica M&#xe9;dica Sur, A.C. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Bingzheng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhikai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haifang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hepatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address: daweiy2@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Ann Hepatol</MedlineTA><NlmUniqueID>101155885</NlmUniqueID><ISSNLinking>1665-2681</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bevacizumab</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">HCC</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">TACE</Keyword></KeywordList><CoiStatement>Declaration of interests None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40897264</ArticleId><ArticleId IdType="doi">10.1016/j.aohep.2025.102106</ArticleId><ArticleId IdType="pii">S1665-2681(25)00331-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>